Delivery of inhaled medication to children

Journal of Asthma

Volumn 34, Issue 6, 1997, Pages 443-467

  Bisgaard, Hans ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT;

AEROSOL; ASTHMA; CHILD; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TISSUE LEVEL; ENVIRONMENTAL FACTOR; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; REVIEW;

EID: 0031458469     PISSN: 02770903     EISSN: None     Source Type: Journal    
DOI: 10.3109/02770909709055389     Document Type: Review

References (173)

1. Warner J: Asthma: A follow up statement from an international paediatric asthma consensus group. Arch Dis Child 67: 240-248 (1992).
2. Bisgaard H, Munck SL, Nielsen JP, Petersen W, Ohlsson SV: Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet 336:649-651 (1990).
3. Noble V, Ruggins R, Everard ML, Milner AD: Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child 67:285-288 (1992).
4. Connett GJ, Warde C, Wooler E, Lenney W: Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child 69:351-355 (1993).
5. Everard ML, Hardy JG, Milner AD: Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax 48:1045-1046 (1993).
6. Chua HL, Collis GG, Newbury AM, Chan K, Bower GD, Sly PD, Le Souef PN: The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 7:2185-2191 (1994).
7. Becquemin MH, Swift DL, Bouchikhi A, Roy M, Teillac A: Particle deposition and resistance in the noses of adults and children. Eur Respir J 4:694-702 (1991).
8. Olsson B: Aerosol particle generation from dry powder inhalers: Can they equal pressurized metered dose inhalers? J Aerosol Med 8:S13-18 (1995).
9. O'Doherty MJ, Thomas SHL, Gibb D, Page CJ, Harrington C, Duggan C, Nunan TO, Bateman NT: Lung deposition of nebulised pentamidine in children. Thorax 48:220-226 (1993).
10. Tal A, Golan H, Grauer N, Aviram M, Albin D, Quastel MR: Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 128:479-484 (1996).
11. Everard ML, Devadason SG, Macerlean C, Roller C, Summers O, Swift P, Borgström L, Le Souef PN: Drug delivery from turbuhaler to children with cystic fibrosis. Am J Respir Crit Care Med 153(4):A70 (1996).
12. Thomas SHL, Batchelor S, O'Doherty MJ: Therapeutic aerosols in children. Br Med J 307:245-247 (1993).
13. Everard ML: Studies using radiolabeled aerosols in children. Thorax 49:1259-1266 (1994).
14. Salmon B, Wilson NM, Silverman M: How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 65:401-403 (1990).
15. Hindle M, Chrystyn H: Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 34:311-315 (1992).
16. Borgström L, Nilsson M: A method for determination of the absolute pulmonary bioavailability of inhaled drugs: Terbutaline. Pharm Res 7:1068-1070 (1990).
17. Thorsson L, Edsbäcker S, Conradson TB: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler P-MDI. Eur Respir J 7:1839-1844 (1994).
18. Lippmann M, Yeates DB, Albert RE: Deposition, retention and clearance of inhaled particles. Br J Ind Med 37:337-362 (1980).
19. Gonda I: A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J Pharm Pharmacol 33:692-696 (1981).
20. Heyder J: Alveolar deposition of inhaled particles in humans. Am Ind Hyg Assoc J 43:864-866 (1982).
21. Stahlhofen W, Rudolf G, James AC: Intercomparison of experimental regional aerosol deposition data. J Aerosol Med 2:285-308 (1989).
22. Agnew JE: Characterizing lung aerosol penetration. J Aerosol Med 4:237-249 (1991).
23. Martonen TB, Katz I: Deposition patterns of polydisperse aerosols within human lungs. J Aerosol Med 6:251-274 (1993).
24. Perring S, Summers Q, Fleming JS, Nassim MA, Holgate ST: A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol 67:46-53 (1994).
25. Holgate ST, Fleming JS, Conway J, Hashish AH, Nassim MA, Halson P, Moore E, Bailey AG: Assessment of deposition of inhaled aerosol in the respiratory tract of man using three dimensional multimodality imaging and mathematical modelling. In Respiratory Drug Delivery V (Dalby RN, Byron PR, Farr SY, editors). Interpharm Press, Phoenix, AZ, Buffalo Grove, IL, 1996, 1-10.
26. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys 12:173-208 (1966).
27. Agnew JE: Bronchiolar aerosol deposition and clearance. Eur Respir J 9:1118-1122 (1996).
28. Persson G, Wiren JE: The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbuhaler). Eur Respir J 2:253-256 (1989).
29. Rees PJ, Clark TJH, Moren F: The importance of particle size response to inhaled bronchodilators. Eur J Respir Dis 63:73-8 (1982).
30. Clay MM, Pavia D, Clarke SW: Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax 41:364-368 (1986).
31. Clay MM, Clarke SW: Effect of nebulised aerosol size on lung deposition in patients with mild asthma. Thorax 42:190-194 (1987).
32. Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW: Delivery of albuterol and ipratropium bromide from two nebuliser systems in chronic stable asthma. Chest 96:1-10 (1989).
33. Borgstöm L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R: The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 153:1636-1640 (1996).
34. Zanen P, Go LT, Lammers JWJ: The optimal particle size for beta-adrenergic aerosols in mild asthmatics. Int J Pharm 107:211-217 (1994).
35. Patel P, Mukai D, Wilson AF: Dose-response effects of two sizes of monodisperse isoproterenol in mild asthma. Am Rev Respir Dis 141:357-360 (1990).
36. Dolovich M, Ryan G, Newhouse MT: Aerosol penetration into the lung. Chest 80(Suppl):834 (1981).
37. Mitchell DM, Solomon MA, Tolfree SEJ, Short M, Spiro SG: Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. Thorax 42:457-461 (1987).
38. Zainudin BMZ, Tolfree SEJ, Short M, Spiro SG: Influence of breathing pattern on lung deposition and bronchodilator response to nebulised salbutamol in patients with stable asthma. Thorax 43: 987-991 (1988).
39. Olsson B, Borgström L, Asking L, Bondesson E: Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In Respiratory Drug Delivery V (Dalby RN, Byron PR, Farr SY, editors). Interpharm Press, Phoenix AZ. Buffalo Grove, IL, 1996, 273-281.
40. Berg E: Dose characterization from a pMDI and a new-spacer with and without a cast of the throat of a child. In Respiratory Drug Delivery V (Dalby RN, Byron PR, Farr SY, editors). Interpharm Press, Phoenix AZ. Buffalo Grove, IL, 1996, 308-309.
41. Bisgaard H, Berg E: Cast of human airways from the lips to the trachea for in vitro estimate of lung dose. Eur Respir J 10:236 (1997).
42. Bisgaard H: Drug delivery from inhaler devices. Br Med J 313:895-896 (1996).
43. Derom E, Pauwels R: Bioequivalence of inhaled drugs. Eur Respir J 8:1634-1636 (1995).
44. Rogers DF, Ganderton D, editors: Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research. Respir Med 89:253-261 (1995).
45. Blake KV, Harman E, Hendeles L: Evaluation of a generic albuterol metered-dose inhaler. Importance of priming the MDI. Ann Allergy 68:169-174 (1992).
46. Miller MR, Bright P: Differences in output from corticosteroid inhalers used with a volumatic spacer. Eur Respir J 8:1637-1638 (1995).
47. Kenyon CJ, Dewsbury NJ, Newman SP: Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacer. Thorax 50:846-850 (1995).
48. Pierce AK, Sandford JP, Thomas GD, Leonard JS: Long-term evaluation of decontamination of inhalation therapy equipment and occurrence of necrotizing pneumonia. N Engl J Med 282:528-531 (1970).
49. Barnes KL, Clifford R, Holgate ST, Murphy D, Comber P, Bell E: Bacterial contamination of home nebulisers. Br Med J 295:812 (1987).
50. Pedersen S: Inhaler use in children with asthma. Danish Med Bull 34:234-249 (1987).
51. Pedersen S: Inhalers and nebulizers: Which to choose and why. Respir Med 90:69-77 (1996).
52. Newman SP: Metered dose pressurized aerosols and the ozone layer. Eur Respir J 3:495-497 (1990).
53. Balmes JR: The environmental impact of chlorofluorocarbon use in metered dose inhalers. Chest 100:1101-1102 (1991).
54. Pavia D, McLeod L: The environmental impact of inhaled aerosols. Eur Respir Rev 4:75-77 (1994).
55. D'Souza S: The Montreal Protocol and essential use exemptions. J Aerosol Med 8:S13-17 (1995).
56. Isaksen ISA: Dual effects of ozone reduction. Nature 372:322-323 (1994).
57. Smith R: Doctors and climatic change. Br Med J 309: 1384-1385 (1994).
58. Hileman B: Scientists warn that disease threats increase as earth warms up. C & EN 2:19-20 (1995).
59. Marshall LM, Francis PW, Khafagi FA: Aerosol deposition in cystic fibrosis using an aerosol conservation device and a conventional jet nebulizer. J Paediatr Child Health 30:65-67 (1994).
60. Mukhopadhyay S, Staddon GE, Estman C, Palmer M, Rhys Davies E, Carswell F: The quantitative distribution of nebulized antibiotics in the lung in cystic fibrosis. Respir Med 88:203-211 (1994).
61. Thomas SHL, O'Doherty MJ, Page CJ, Nunan TO, Bateman NT: Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J 4:616-622 (1991).
62. Lewis RA, Fleming JS: Fractional deposition from a jet nebulizer: How it differs from a metered dose inhaler. Br J Dis Chest 79:361-367 (1985).
63. Zainudin BMZ, Biddiscombe M, Tolfree SEJ, Short M, Spiro SG: Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 45:469-473 (1990).
64. Collis G, Cole CH, Le Souef PN: Dilution of nebulised aerosols by air entrainment in children. Lancet 336:341-343 (1990).
65. Smith EC, Denyer J, Kendrick AH: Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 8:1214-1221 (1995).
66. Clay MM, Pavia D, Newman SP, Lennard-Jones T, Clarke SW: Assessment of jet-nebulisers for lung aerosol therapy. Lancet 2:592-594 (1983).
67. Newman SP, Pellow PGD, Clay MM, Clarke WS: Evaluation of jet nebulisers for use with gentamicin solution. Thorax 40:671-676 (1985).
68. Phipps PR, Gonda I: Droplets produced by medical nebulizers. Chest 97:1327-1332 (1990).
69. Brockbank W, Brebner H, Pengelly CDR: Chronic asthma treated with aerosol hydrocortisone. Lancet 2:807 (1956).
70. Morrison Smith J: Hydrocortisone hemisuccinate by inhalation in children with asthma. Lancet 2: 1248-1249 (1958).
71. O'Callaghan C: Particle size of beclomethasone dipropionate produced by two nebulisers and two spacing devices. Thorax 45:109-111 (1990).
72. Webb MSC, Milner AD, Hiller EJ, Henry RL: Nebulised beclomethasone dipropionate suspension. Arch Dis Child 61:1108-1110 (1986).
73. Storr J, Lenney CA, Lenney W: Nebulised beclomethasone dipropionate in preschool asthma. Arch Dis Child 61:270-273 (1986).
74. Bisgaard H, Nikander K, Munch E: Comparative study of budesonide as a nebulized suspension versus pressurized metered dose inhaler in adult asthmatics. Respir Med 92 (in press).
75. Bisgaard H: Aerosol treatment of young children. Eur Respir Rev 4:15-20 (1994).
76. Schöni MH, Kraemer R: Osmolality changes in nebuliser solutions. Eur Respir J 2:887-892 (1989).
77. O'Callaghan C, Milner AD, Swarbrick A: Paradoxical deterioration in lung function after nebulized salbutamol in wheezy infants. Lancet 2:1424-1425 (1986).
78. O'Callaghan C, Milner AD, Swarbrick A: Paradoxical bronchoconstriction in wheezing infants after nebulised preservative free iso-osmolar ipratropium bromide. Br Med J 299:1433-1434 (1989).
79. Cochetto D, Sykes RS, Spector S: Paradoxical bronchospasm after use of inhalation aerosols: A review of the literature. J Asthma 28:49-53 (1991).
80. Dolovich MB, Ruffin RE, Roberts R, Newhouse MT: Optimal delivery of aerosols from metered dose inhalers. Chest 80(Suppl):911-915 (1981).
81. Newman SP, Pavia D, Moren F, Sheahan NF, Clarke SW: Deposition of pressurised aerosols in the human respiratory tract. Thorax 36:52-55 (1981).
82. Melchor R, Biddiscombe MF, Mak VHF, Short MD, Spiro SG: Lung deposition patterns of directly labeled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511 (1993).
83. Matthys H, Eltschka R, App EM: Deposition of a labeled beta2-agonist aerosol. Atemwlungenkrkn 10:485-488 (1988).
84. Farr SJ, Rowe AM, Rubsamen R, Taylor G: Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. Thorax 50:639-644 (1995).
85. King D, Earnshaw SM, Delaney JC: Pressurised aerosol inhalers: The cost of misuse. Br J Gen Pract 45:48-49 (1991).
86. Byron PR: Dosing reproducibility from experimental albuterol suspension metered-dose inhalers. Pharm Res 11:580-584 (1994).
87. Pedersen S: Aerosol treatment of bronchoconstriction in children with or without a tube spacer. N Engl J Med 308:1328-1330 (1983).
88. Pedersen S, Østergaard PA: Nasal inhalation as a cause of inefficient pulmonary aerosol inhalation technique in children. Allergy 38:191-194 (1983).
89. Pedersen S, Frost L, Arnfred T: Errors in inhalation technique and efficiency in inhaler use in asthmatic children. Allergy 41:118-124 (1986).
90. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM: The influence of age, diagnosis and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 150:1256-1261 (1994).
91. Thompson J, Irvine T, Grathwohl K, Roth B: Misuse of metered-dose inhalers in hospitalized patients. Chest 105:715-717 (1994).
92. Hilton S: An audit of inhaler technique among asthma patients of 34 general practitioners. Br J Gen Pract 40:505-506 (1990).
93. Guidry GG, Brown WD, Stogner SW, George RB: Incorrect use of metered dose inhalers by medical personnel. Chest 101:31-33 (1992).
94. Ruggins NR, Milner AD, Swarbrick A: An Assessment of a new breath actuated inhaler device in acutely ill wheezy children. Arch Dis Child 68:477-480 (1993).
95. Newman SP, Weisz AW, Talaee N, Clarke SW: Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax 46:712-716 (1991).
96. Leach C: Enhanced drug delivery through reformulating MDIs with HFA propellants - drug deposition and its effect on preclinical and clinical programs. In Respiratory Drug Delivery V (Dalby RN, Byron PR, Farr SY, editors). Interpharm Press, Phoenix, AZ. Buffalo Grove, IL, 1996, 133-144.
97. Clark DJ, Lipworth BJ: Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 41:247-249 (1996).
98. Hampson NB, Mueller MP: Cooling of metered-dose inhalers decreases pressure output from cannisters. N Engl J Med 320:321 (1989).
99. Everard ML, Devadason SG, Summers QA, Le Souef PN: Factors affecting total and "respirable" dose delivered by a salbutamol metered dose inhaler. Thorax 50:746-749 (1995).
100. Cyr TD, Graham SJ, Li RKY, Lovering EG: Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 8:658-660 (1991).
101. Borgström L: Methodological studies on lung deposition. Evaluation of inhalation devices and absorption mechanisms. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 105. Acta Univ Uppsala, Uppsala, 1993, 1-51.
102. Newman SP: Deposition and effects of inhalation aerosols. Thesis, Rahms Tryckeri, Lund, 1983.
103. Graff-Lonnevig V: Diurnal expiratory flow after inhalation of freons and fenoterol in childhood asthma. J Allergy Clin Immunol 64:534-538 (1979).
104. Yarborough J, Mansfield LE, Ting S: Metered dose inhaler induced bronchospasm in asthmatic patients. Ann Allergy 55:25-27 (1985).
105. Nicklas RA: Paradoxical bronchospasm associated with the use of inhaled beta-agonists. J Allergy Clin Immunol 85:959-964 (1990).
106. Engel T: Patient-related side effects of CFC propellants. J Aerosol Med 3:163-167 (1991).
107. Wilkinson JRW, Roberts JA, Bradding P, Holgate ST, Howarth PH: Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler. Br Med J 305:931-932 (1992).
108. Jackson L, Ståhl E, Holgate ST: Terbutaline via pressurised metered dose inhaler (pMDI) and Turbuhaler in highly reactive asthmatic patients. Eur Respir J 7:1598-1601 (1994).
109. Selroos O, Lofroos AB, Pietinalho A, Riska H: Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 49:1228-1230 (1994).
110. Shaheen MZ, Ayres JG, Benincasa C: Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients. Eur Respir J 7:2160-2164 (1994).
111. Williams DJ, Williams AC, Kruchek DG: Problems in assessing contents of metered dose inhalers. Br Med J 307:771-772 (1993).
112. Newman S, Millar AB, Lennard-Jones TR, Moren F, Clarke S: Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 39:935-941 (1984).
113. Newman SP, Steed K, Hooper G, Källén A, Borgström L: Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurized metered dose inhaler. Pharm Res 12:231-236 (1995).
114. Vidgren P, Vidgren M, Paronen P, Vainio P, Nuutinen J: Effects of inspirease holding chamber on the deposition of metered close inhalation aerosols. Eur J Drug Metab Pharmcokinet (Spec No 3):419-425 (1991).
115. Bisgaard H: Dose of aerosol inhaled in young children from a small-volume spacer. Eur J Respir Dis 6:352 (1993).
116. Bisgaard H: A metal aerosol holding chamber devised for young children with asthma. Eur Respir J 8:856-860 (1995).
117. Bisgaard H, Anhoj J, Klug B, Berg E: A non-electrostatic spacer for aerosol delivery. Arch Dis Child 73:226-230 (1995).
118. O'Callaghan C, Lynch J, Cant M, Robertson C: Improvement in sodium cromoglycate delivery from a spacer device by use of antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax 48:603-606 (1993).
119. Barry PW, O'Callaghan C: The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol 40:76-78 (1995).
120. Fuglsang G, Pedersen S: Cumulative dose response relationship of terbutaline delivered by three different inhalers. Allergy 43:348-352 (1988).
121. Hindle M, Chrystyn H: Nebuhaler and volumatic improve pulmonary delivery. Arch Dis Child 67:580-585 (1992).
122. Kraemer R, Frey U, Sommer CW, Russi E: Short-term effect of albuterol, delivered via a new auxiliary device in wheezy infants. Am Rev Respir Dis 144:347-351 (1991).
123. Franklin W, Lowell FC, Michelson AL, Schiller IW: Aerosolized steroids in bronchial asthma. J Allergy 29:214-221 (1958).
124. Kenyon CJ, Thorsson L, Borgström L, Newman SP: The effects of static charge in spacer devices on glucocorticosteroid aersol deposition in asthmatic patients. Eur Respir J 1997 (in press).
125. Moren F: Drug deposition of pressurized inhalation aerosols. Influence of actuator tube design. Int J Pharm 1:205-212 (1978).
126. Bisgaard H, Berg E, Madsen J: Dose delivery and fine particle dose of aerosol from three spacers intended for asthma treatment in young children. Eur Respir J 9(Suppl 23):431S (1996).
127. Wildhaber JH, Devadason SG, Hayden MJ, James R, Dufty AP, Fox RA, Summers QA, LeSouëf PN: Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J 9:1943-1946 (1996).
128. Matthys H: Inhalation delivery of asthma drugs. Lung 168:645-652 (1990).
129. Fields MR: US Patent 2470296, 1946.
130. Herxheimer H, McAllen MK, Williams DA: Local treatment of bronchial asthma with hydrocortisone powder. Br Med J 2:762-765 (1958).
131. Helm WB, Heyworth F: Bronchial asthma and chronic bronchitis treated with hydrocortisone acetate inhalations. Br Med J 1:765-768 (1958).
132. Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén J-E: Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43:155-161 (1997).
133. Bisgaard H, Andersen JB, Mortensen NB, Bertelsen A, Friis B, Koch C, Prahl P, Wickmann R, Østerballe O: A clinical comparison of aerosol and powder administration of beclomethasone dipropionate in childhood asthma. Allergy 39:365-369 (1984).
134. Borgström L, Newman S: Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via Turbuhaler. Int J Pharm 97:47-53 (1993).
135. Borgström L, Newman SF, Weisz A, Moren F: Pulmonary deposition of inhaled terbutaline: Comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 81:753-755 (1992).
136. Ekström T, Andersson A-C, Skedinger M, Lindbladh C, Ståhl E: Dose potency relationship of terbutaline inhaled via Turbuhaler or via a pressurized metered dose inhaler. Int Allergy 74:328-332 (1995).
137. Löfdahl CC, Andersson L, Bondesson E, Carlsson LG, Friberg K, Hornblad Y, Jemsby P, Rosenborg J, Werner S, Svedmyr N: Salbutamol doses inhaled via Turbuhaler gives a better bronchodilating effect than when given via a pressurized metered dose inhaler. Eur Respir J 7:49s (1994).
138. Matusiewicz SP, Bollert FG, Dewar M, Brown G, McLean A, Greening AP, Crompton GK: Ipratropium bromide given by Turbohaler is more potent than when given by pressurised dose inhaler (MDI). Thorax 50:469P (1995).
139. Agertoft L, Pedersen S: Importance of the inhalation device on the effect of budesonide. Arch Dis Child 69:130-133 (1993).
140. Hultquist C, Ahlström H, Kjellman NIM, Malmqvist L-Å,Svenonius E, Melin S: A double-blind comparison between a new multiple dose powder inhaler (Turbuhaler) and metered-dose inhaler in children with asthma. Allergy 44:467-470 (1989).
141. Osterman K, Norborg AM, Stähl E: A multiple dose powder inhaler (Turbuhaler) compared with a conventional aerosol. Allergy 44:294-297 (1989).
142. Svenonius E, Arborelius M, Wiberg R, Ståhl E, Svensson M: A comparison of terbutaline inhaled by Turbuhaler and by chlorofluorocarbon (CFC) inhaler in children with exercise-induced asthma. Allergy 49:408-412 (1994).
143. Johnsen CR, Weeke ER: Turbuhaler: a new device for dry powder terbutaline inhalation. Allergy 43:392-395 (1988).
144. Svartengren K, Lindestad P-Å, Svartengren M, Philipson K, Bylin G, Camner P: Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 152:32-37 (1995).
145. Bisgaard H, Klug PKP, Burnell P, Sumby BS: Use of inhalation profiles from paediatric asthmatics using the diskus and turbuhaler inhalers to evaluate product performance in-vitro. Am J Rispir Crit Care Med 153(4): A75 (1996).
146. Hindle M, Byron PR: Dose emission from marketed dry powder inhalers. Int J Pharm 16:1-9 (1994).
147. Meakin BJ, Cainev JM, Woodcock PM: Drug delivery characteristics of Bricanyl Turbuhaler dry powder inhalers. Int J Pharm 119:91-102 (1995).
148. Olsson B, Asking L: Critical aspects of the function of inspira tory flow driven inhalers. J Aerosol Med 7:S43-17 (1994).
149. Brindley A, Sumby BS, Smith IJ: The characterisation of inhalation devices by an inhalation simulator: the electronic lung. J Aerosol Med 7:197-200 (1994).
150. Bisgaard H, Pedersen S, Nikander K: Use of budesonide Turbuhaler in young children suspected of asthma. Eur Respir J 7:740-742 (1994).
151. Newman SP, Morén F, Trofast E, Talaee N, Clarke SW: Terbutaline sulphate Turbuhaler: Effect of inhaled flow rate on drug deposition and efficacy. Int J Pharm 74:209-213 (1991).
152. Newman SP, Hollingworth A, Clark AR: Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 102:127-132 (1994).
153. Borgström L, Bondesson E, Moren F, Trofast E, Newman SP: Lung deposition of budesonide inhaled via Turbuhaler. A comparison with terbutaline sulphate in normal subjects. Eur Respir J 7:69-73 (1994).
154. Pedersen S, Hansen OR, Fuglsang G: Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 65:308-310 (1990).
155. Engel T, Scharling B, Skovsted B, Heinig JH: Effects, side effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from dry powder inhaler device at different inhalations and flows and volumes. Br J Clin Pharmacol 33:439-444 (1992).
156. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST: Absorption and disposition kinetics of croomolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 241:1028-1032 (1987).
157. Auty RM, Brown K, Neale MG, Snashall PD: Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br J Dis Chest 81:371-380 (1987).
158. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H: Flow dependent effect of the formoterol dry powder inhaler. Eur Respir J 9:432s (1996).
159. Nielsen KG, Auk IL, Bojsen K, Bisgaard H: Effects of salmeterol 5 micg inhaled at high and low flow rates from a Diskus Inhaler. Eur Respir J 9:287s (1996).
160. Borgström L, Asking L, Beckman O, Bondesson E, Källén A, Olsson B: Dose variation within and between individuals, with different inhalation systems. In Respiratory Drug Delivery V (Dalby RN, Byron PR, Farr SY, editors). Interpharm Press, Phoenix AZ. Buffalo Grove, IL, 1996, 19-24.
161. Laberge S, Spier S, Drblik SP, Turgeon JP: Comparison of inhaled terbutaline administered by either Turbuhaler dry powder inhaler or a metered-dose inhaler with spacer in preschool children with asthma. J Pediatr 124:815-817 (1994).
162. Goren A, Noviski N, Avital A, Maayan C, Ståhl E, Godfrey S, Springer C: Assessment of the ability of young children to use a powder inhaler device (Turbuhaler). Pediatr Pharmacol 18:77-80 (1994).
163. Pendergast J, Hopkins J, Timms B, Van Asperen PP: Comparative efficacy of terbutaline administered by Nebuhaler and by nebulizer in young children with acute asthma. Med J Aust 151:406-408 (1989).
164. Lin YZ, Hsieh KH: Metered dose inhaler and nebuliser in acute asthma. Arch Dis Child 72:214-218 (1995).
165. Newman SP, Steed KP, Reader SJ, Hooper C, Zierenberg B: Efficient delivery to the lungs of flunisolide from a portable hand-held multidose nebulizer. J Pharm Sci 85:960-964 (1996)
166. Gupte AR, Hochrainer D, Poss G, Wittekind J, Zierenberg B, Knecht A: Patent application WO 92/00115, 1992.
167. Galli R: Patent application WO 93/18812, 1993.
168. Bruna P, Pourment O, Williams G: In-vitro characterisation of a new dry powder inhaler, the Prohaler, with two hydrophilic drugs in normal and humid conditions. In Respiratory Drug Delivery IV (Byron P, Dalby RN, Farr SJ, editors.) Interpharm Press, Buffalo Grove, IL, 1994, 352-354.
169. Jäger-Waldau R, Mehring H, Wiggins JD: Feasibility of a low dosage dynamic powder dispenser for drug delivery to the lungs. J Aerosol Med 7:205-208 (1994).
170. Micikalski MB, Williams DR: Patent application WO 94/08552, 1994.
171. Hill M: Characteristics of an active multiple dose dry powder inhaler. In Respiratory Drug Delivery IV (Byron P, Dalby RN, Farr SJ, editors). Interpharm Press, Buffalo Grove, IL, 1994, 109-116.
172. Schultz RK, Miller NC, Smith DK, Ross DL: Powder aerosols with auxiliary means of dispersion. J Biopharm Sci 3:115-121 (1992).
173. Bisgaard H: European Patent no. EP548152.